MAPK3 and cervical cancer: These results suggest that zoledronic acid targeted cervical cancer cells derived CSCs possibly by suppressing phosphorylated Erk1/2 and Akt and this might be closely associated with the sensitivity of zoledronic acid on cervical cancer cells derived CSCs but not the parental cervical cancer cells.